Status:
COMPLETED
Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to permit the patients with schizophrenia who received Sertindole during a previous randomised trial, study 99824, to continue with this treatment.
Detailed Description
Schizophrenia is a disabling and often chronic disorder that may require long-term treatment. This protocol is an extension study of a randomised study comparing the safety of Sertindole versus Risper...
Eligibility Criteria
Inclusion
- Participation in the previous SCoP study, 99824
- Still fulfils the EU SPC requirements for Sertindole
Exclusion
- Withdrawn before the end of the SCoP study, 99824
- Become homeless
- Participation in another clinical trial at the same time
- Unlikely to comply with the clinical study protocol or is unsuitable for any reason
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00763438
Start Date
November 1 2007
End Date
October 1 2010
Last Update
November 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
FR002
Allonnes, France, 72703